FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983302016> ?p ?o ?g. }

• W2983302016 abstract "Abstract Background Refractory cancers pose formidable management challenges. We hypothesized that such malignancies have unexplored vulnerabilities that can be identified using Encyclopedic Tumor Analysis (ETA) and effectively targeted using conventional agents in a label- and organ-agnostic manner to yield treatment benefit. The pan-cancer RESILIENT trial addressed patients with advanced refractory malignancies who were treated with ETA guided treatments regimens without any restrictive eligibility criteria. Methods Molecular Profiling (MP) of patients’ fresh tumor tissue interrogated gene alterations and differentially regulated metabolic pathways to identify molecular targets of approved anticancer agents in a label-agnostic manner. Immunohistochemistry (IHC) identified hormone receptors (HR) that could be targeted with endocrine agents. Chemoresistance and response (CRR) profiling of viable tumor derived cells (TDCs) identified functional vulnerabilities of the tumor against a panel of systemic anticancer agents. Synergistic integration of MP, IHC and CRR datasets (i.e., ETA) generated patient-specific drug priority lists with projected efficacy and safety. Patients who received such ETA-guided treatments were evaluated by PET-CT scans to determine treatment response as well as Objective Response Rate (ORR), Disease Control Rate (DCR) and Progression Free Survival (PFS). Results Among the 200 patients who were screened, 110 patients received ETA-guided treatments and were evaluable for response per protocol. PR was observed in 47 patients (ORR = 42.7%) and 99 patients continued to exhibit PR or SD at study termination (DCR = 90%). Median PFS was 125 days. Median PFS rate at 90 days was 94.0%. No significant therapy related adverse events (AEs) were noted – there were no grade IV AEs or treatment related deaths. Most patients reported stable to improved Quality of Life (QoL) in terms of disease-related symptoms and functional status. Conclusions ETA-guided treatments offer meaningful survival benefits and outperformed available alternatives including checkpoint inhibitors in this heavily pretreated pan-cancer population. Legal entity responsible for the study The authors. Funding Datar Cancer Genetics Limited. Disclosure D. Patil: Full / Part-time employment: Datar Cancer Genetics Limited. D. Akolkar: Full / Part-time employment: Datar Cancer Genetics Limited. V. Datta: Full / Part-time employment: Datar Cancer Genetics Limited. A. Ghaisas: Full / Part-time employment: Datar Cancer Genetics Limited. R. Patil: Full / Part-time employment: Datar Cancer Genetics Limited. H. Singh: Full / Part-time employment: Datar Cancer Genetics Limited. A. Srinivasan: Full / Part-time employment: Datar Cancer Genetics Limited. S. Apurwa: Full / Part-time employment: Datar Cancer Genetics Limited. R. Datar: Shareholder / Stockholder / Stock options, Licensing / Royalties, Officer / Board of Directors: Datar Cancer Genetics Limited. All other authors have declared no conflicts of interest." @default.
• W2983302016 created "2019-11-22" @default.
• W2983302016 creator A5015926221 @default.
• W2983302016 creator A5034756571 @default.
• W2983302016 creator A5035436218 @default.
• W2983302016 creator A5042021541 @default.
• W2983302016 creator A5047835983 @default.
• W2983302016 creator A5047983896 @default.
• W2983302016 creator A5056770144 @default.
• W2983302016 creator A5057697338 @default.
• W2983302016 creator A5066075688 @default.
• W2983302016 creator A5069922846 @default.
• W2983302016 creator A5083797029 @default.
• W2983302016 creator A5087494976 @default.
• W2983302016 creator A5087680459 @default.
• W2983302016 date "2019-11-01" @default.
• W2983302016 modified "2023-09-27" @default.
• W2983302016 title "Encyclopedic tumour analysis guided treatments with conventional drugs outperform available alternatives in refractory cancers" @default.
• W2983302016 doi "https://doi.org/10.1093/annonc/mdz413.098" @default.
• W2983302016 hasPublicationYear "2019" @default.
• W2983302016 type Work @default.
• W2983302016 sameAs 2983302016 @default.
• W2983302016 citedByCount "0" @default.
• W2983302016 crossrefType "journal-article" @default.
• W2983302016 hasAuthorship W2983302016A5015926221 @default.
• W2983302016 hasAuthorship W2983302016A5034756571 @default.
• W2983302016 hasAuthorship W2983302016A5035436218 @default.
• W2983302016 hasAuthorship W2983302016A5042021541 @default.
• W2983302016 hasAuthorship W2983302016A5047835983 @default.
• W2983302016 hasAuthorship W2983302016A5047983896 @default.
• W2983302016 hasAuthorship W2983302016A5056770144 @default.
• W2983302016 hasAuthorship W2983302016A5057697338 @default.
• W2983302016 hasAuthorship W2983302016A5066075688 @default.
• W2983302016 hasAuthorship W2983302016A5069922846 @default.
• W2983302016 hasAuthorship W2983302016A5083797029 @default.
• W2983302016 hasAuthorship W2983302016A5087494976 @default.
• W2983302016 hasAuthorship W2983302016A5087680459 @default.
• W2983302016 hasBestOaLocation W29833020161 @default.
• W2983302016 hasConcept C121332964 @default.
• W2983302016 hasConcept C126322002 @default.
• W2983302016 hasConcept C142424586 @default.
• W2983302016 hasConcept C143998085 @default.
• W2983302016 hasConcept C197934379 @default.
• W2983302016 hasConcept C204232928 @default.
• W2983302016 hasConcept C2780739268 @default.
• W2983302016 hasConcept C3019894029 @default.
• W2983302016 hasConcept C71924100 @default.
• W2983302016 hasConcept C87355193 @default.
• W2983302016 hasConceptScore W2983302016C121332964 @default.
• W2983302016 hasConceptScore W2983302016C126322002 @default.
• W2983302016 hasConceptScore W2983302016C142424586 @default.
• W2983302016 hasConceptScore W2983302016C143998085 @default.
• W2983302016 hasConceptScore W2983302016C197934379 @default.
• W2983302016 hasConceptScore W2983302016C204232928 @default.
• W2983302016 hasConceptScore W2983302016C2780739268 @default.
• W2983302016 hasConceptScore W2983302016C3019894029 @default.
• W2983302016 hasConceptScore W2983302016C71924100 @default.
• W2983302016 hasConceptScore W2983302016C87355193 @default.
• W2983302016 hasLocation W29833020161 @default.
• W2983302016 hasOpenAccess W2983302016 @default.
• W2983302016 hasPrimaryLocation W29833020161 @default.
• W2983302016 hasRelatedWork W10386318 @default.
• W2983302016 hasRelatedWork W13474352 @default.
• W2983302016 hasRelatedWork W1618377 @default.
• W2983302016 hasRelatedWork W16896924 @default.
• W2983302016 hasRelatedWork W17437393 @default.
• W2983302016 hasRelatedWork W18979795 @default.
• W2983302016 hasRelatedWork W2337926 @default.
• W2983302016 hasRelatedWork W3657330 @default.
• W2983302016 hasRelatedWork W5346711 @default.
• W2983302016 hasRelatedWork W17830138 @default.
• W2983302016 isParatext "false" @default.
• W2983302016 isRetracted "false" @default.
• W2983302016 magId "2983302016" @default.
• W2983302016 workType "article" @default.